Rapid advances in viral vectors, advanced plasmid DNA and oncology drive new expansion in global markets.Austin, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Gene Therapy Starting Materials Market Size & Growth ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a ...
FutureWise Research, a leading global market intelligence firm, today released a landmark report on Plasmid DNA Manufacturing ...
DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...
About EG 427 EG 427 is the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. EG 427 has started a phase 1/2 study in the US with its lead DNA medicine candidate, EG110A, ...
Researchers found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years and ...
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill ...
OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback